This message contains images. If you don't see images, click here to view.
Advertise in this news brief.

Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit          

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store


Bevacizumab approved in England for advanced cervical cancer
The Guardian
Women in England who are dying of cervical cancer are to receive a drug that could extend their lives by as much as four months. Women with advanced cervical cancer will be able to get Avastin, which is also known as bevacizumab, after NHS England decided to fund courses of treatment with it for such patients. Avastin is already used to treat advanced forms of breast, lung, bowel, ovarian and kidney cancer. NHS England has now included it on the Cancer Drugs Fund's list of approved medications for use by cervical cancer sufferers who are near the end of their lives.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Targeted drug shows promise in cervical cancer
Science Codex
The epidermal growth factor receptor inhibitor erlotinib appears to be effective in locally advanced cervical cancer, Brazilian researchers have found in a breakthrough study. Published online in Cancer, the study involved 36 women with stage IIB to IIIB epidermoid cervical cancer who were given erlotinib at a dose of 150mg/day one week before and in combination with cisplatin-based chemoradiation.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


ASCO Report: Cancer will be No. 1 killer in US
In 16 years, cancer will become the leading cause of death in the United States, surpassing heart disease, according to a new report from the American Society of Clinical Oncology (ASCO). The number of new cancer cases is expected to increase nearly 45 percent by 2030, from 1.6 million cases to 2.3 million cases annually. This influx of new patients will place a bigger burden on a field of medicine already stretched by physician shortages and financial difficulties, says the report, which highlights growing problems for cancer care in the United States.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.

Report: Excess weight a risk factor for ovarian cancer
HealthDay News
A new report reveals that excess weight raises the risk of yet another kind of cancer, with the latest results linking levels of body fat to ovarian tumors. The chances for developing many cancers — such as postmenopausal breast, colorectal, endometrial, esophageal, kidney, gallbladder and pancreatic cancers — are known to increase with a person's weight, but the evidence for any such link to ovarian cancer has been inconclusive until now, the report authors said.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Cancer screening rates fall below CDC target goals
Medscape (Free login required)
When it comes to cancer screening, the Healthy People initiative is short of meeting its targets, particularly for certain population subgroups. From 2008 to 2010, overall rates of breast and cervical cancer screening slightly decreased, but screening rates for colorectal cancer rose by 7 percentage points. The rates of cancer screening and counseling by healthcare providers were also below designated targets. "Our report tracks established Healthy People objectives," said report author Carrie N. Klabunde, Ph.D., an epidemiologist in the Health Services and Economics of the National Cancer Institute. "There are Healthy People objectives and target screening rates for breast, cervical, and colorectal cancer screening, all of which are recommended by the US Preventive Services Task Force."
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Patentholder on breast cancer tests denied injunction in lawsuit
The New York Times
Myriad Genetics, which lost a closely watched Supreme Court case last year involving the patenting of genes, has suffered another setback in its efforts to protect its main genetic test from competition. A federal judge denied Myriad’s request for a preliminary injunction that would have immediately stopped a rival company, Ambry Genetics, from offering a similar test. Myriad’s lucrative monopoly on testing for mutations in two genes linked to breast cancer risk was shattered last June by the Supreme Court’s ruling that genes were not eligible for patents because they were products of nature.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Yoga may help breast cancer patients
HealthDay News via WebMD
Women with breast cancer who practiced yoga had lower levels of stress hormones and new research shows less fatigue and better quality of life, new research shows. "Yoga is having an impact on subjective well-being, as well as better regulation of cortisol, a stress hormone," said study co-author Lorenzo Cohen, director of the integrative medicine program at M.D. Anderson Cancer Center, in Houston. "Better regulation of stress hormones has been linked with better survival and longer survival."
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Trastuzumab/Eribulin combo safe and effective in HER2-positive breast cancer
The first-line combination of trastuzumab and eribulin mesylate demonstrated an objective response rate (ORR) of 71.2 percent with a median progression-free survival (PFS) of 11.6 months in patients with HER2-positive advanced breast cancer, according to final results from a phase II study presented in a poster session at MBCC. “Patients that have HER2-positive disease are now being treated with pertuzumab and trastuzumab in the first-line, T-DM1 in the second-line, at some point maybe lapatinib, or maybe capecitabine plus lapatinib,” said Debu Tripathy, M.D., said.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news

Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063